{
  "data": {
    "indicator": {
      "slug": "new-drugs-approved-after-clinical-trials-cn-registration-category",
      "name": "New drugs approved for marketing after clinical trials (China registration category)",
      "definition": "Number of drugs in China's \"new drug\" registration category (innovative and improved new drugs, including TCM) approved for marketing after clinical trials, as reported by the NMPA Center for Drug Evaluation.",
      "unit": "count",
      "scale": "1",
      "default_unit": "count",
      "default_scale": "1"
    },
    "scale": "1",
    "unit": "count",
    "region": {
      "code": "CN",
      "name": "China",
      "type": "country"
    },
    "points": [
      {
        "period_start": "2025-01-01",
        "period_label": "2025",
        "value": 248,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_V2JYK200N2K5Z3HSF7J660P114",
        "url": "https://statorigin.org/stat/stat_V2JYK200N2K5Z3HSF7J660P114",
        "source_org": "NHSA",
        "source": {
          "org": "National Healthcare Security Administration",
          "org_short_name": "NHSA",
          "document_title": "从“0”到“1”创新能力增强 我国新药研发热度持续攀升",
          "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html",
          "locator": "试验包括新药临床试验和生物等效性试验",
          "published_date": null
        }
      }
    ],
    "available_regions": [
      "CN"
    ]
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}